Condition
Short Stature Children Born Small for Gestational Age (SGA)
Total Trials
3
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 3 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
1 of 0 completed with results
Key Signals
1 with results
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Active Not Recruiting2
Recruiting1
Clinical Trials (3)
Showing 3 of 3 trials
NCT07260500Phase 2RecruitingPrimary
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics
NCT03878446Phase 2Active Not RecruitingPrimary
A Research Study in Children Born Small and Who Stayed Small. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day
NCT02375620Phase 2Active Not RecruitingPrimary
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
Showing all 3 trials